plixorafenib (FORE-8394)

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo, Fore Biotherap

Drug class:

BRAF inhibitor, BRAF V600E inhibitor

Related drugs:

BRAF mutation	Ovarian Cancer	BRAF mutation	Ovarian Cancer	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
BRAF mutation	Thyroid Gland Papillary Carcinoma	BRAF mutation	Thyroid Gland Papillary Carcinoma	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
BRAF mutation	Glioma	BRAF mutation	Glioma	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
BRAF V600	Melanoma	BRAF V600	Melanoma	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600	Pancreatic Cancer	BRAF V600	Pancreatic Cancer	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600	Glioma	BRAF V600	Glioma	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600	Thyroid Gland Anaplastic Carcinoma	BRAF V600	Thyroid Gland Anaplastic Carcinoma	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600	Ovarian Cancer	BRAF V600	Ovarian Cancer	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
AGK-BRAF fusion	Melanoma	AGK-BRAF fusion	Melanoma	FORE-8394 Resistant: C4 – Case Studies FORE-8394 Resistant : C4	FORE-8394 Resistant: C4 – Case Studies FORE-8394 Resistant : C4
BRAF V600E	Melanoma	BRAF V600E	Melanoma	encorafenib + FORE-8394 Sensitive: D – Preclinical encorafenib + FORE-8394 Sensitive : D	encorafenib + FORE-8394 Sensitive: D – Preclinical encorafenib + FORE-8394 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	FORE-8394 Sensitive: D – Preclinical FORE-8394 Sensitive : D	FORE-8394 Sensitive: D – Preclinical FORE-8394 Sensitive : D
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	FORE-8394 Sensitive: D – Preclinical FORE-8394 Sensitive : D	FORE-8394 Sensitive: D – Preclinical FORE-8394 Sensitive : D
TARDBP-BRAF fusion	Melanoma	TARDBP-BRAF fusion	Melanoma	FORE-8394 Resistant: D – Preclinical FORE-8394 Resistant : D	FORE-8394 Resistant: D – Preclinical FORE-8394 Resistant : D
SKAP2-BRAF fusion	Melanoma	SKAP2-BRAF fusion	Melanoma	FORE-8394 Resistant: D – Preclinical FORE-8394 Resistant : D	FORE-8394 Resistant: D – Preclinical FORE-8394 Resistant : D
FKBP15-BRAF fusion	Melanoma	FKBP15-BRAF fusion	Melanoma	FORE-8394 Resistant: D – Preclinical FORE-8394 Resistant : D	FORE-8394 Resistant: D – Preclinical FORE-8394 Resistant : D

plixorafenib (FORE-8394)

Associations
(20)

Associations
(20)

plixorafenib (FORE-8394)

Associations(20)

Associations(20)

Associations
(20)

Associations
(20)